These findings suggest that IL-21-dependent GrB+ Bregs may attenuate local anti-tumor immune responses in a manner similar to Tregs, by directly inhibiting the proliferation of CD4+ and CD8+ effector T cells. The gene discussed is CD8A; the disease is neoplasm.